Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis

Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional therapies for treatment of advanced or metastatic cancer. However, the factors determining which patients benefit the most from anti-PD-1/PD-L1 inhibitors are unknown, making treatment-related decisions difficult. We performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Leitao, Zhang, Leyin, Yu, Jieru, Zhang, Yinan, Pang, Xi, Ma, Chenghao, Shen, Minhe, Ruan, Shanming, Wasan, Harpreet S., Qiu, Shengliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005709/
https://www.ncbi.nlm.nih.gov/pubmed/32034198
http://dx.doi.org/10.1038/s41598-020-58674-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005709/
https://www.ncbi.nlm.nih.gov/pubmed/32034198
http://dx.doi.org/10.1038/s41598-020-58674-4

Ejemplares similares